1.84
-0.07(-3.66%)
Currency In USD
| Previous Close | 1.91 |
| Open | 1.88 |
| Day High | 1.91 |
| Day Low | 1.84 |
| 52-Week High | 3.22 |
| 52-Week Low | 0.51 |
| Volume | 366,819 |
| Average Volume | 4.62M |
| Market Cap | 103.55M |
| PE | -1.88 |
| EPS | -0.98 |
| Moving Average 50 Days | 2.56 |
| Moving Average 200 Days | 1.36 |
| Change | -0.07 |
If you invested $1000 in Spero Therapeutics, Inc. (SPRO) since IPO date, it would be worth $160 as of August 20, 2025 at a share price of $1.84. Whereas If you bought $1000 worth of Spero Therapeutics, Inc. (SPRO) shares 5 years ago, it would be worth $139.61 as of August 20, 2025 at a share price of $1.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025
GlobeNewswire Inc.
Aug 05, 2025 8:05 PM GMT
CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacteria
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
GlobeNewswire Inc.
May 28, 2025 11:00 AM GMT
If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually in the US1 with many cases requiring hospitalizati
Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update
GlobeNewswire Inc.
May 13, 2025 8:01 PM GMT
Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI), including acute pyelonephritis (AP), on track to be completed in Q2 2025Existing cash, together with earned